Abstracts tagged "Cardiovascular disease"

Abstract Number: 2077 • 2017 ACR/ARHP Annual Meeting
Statin Use and Mortality in Gout: A General Population-Based Cohort Study
Sarah Keller¹, Sharan K. Rai², Na Lu¹, Amar Oza³, Yuqing Zhang⁴ and Hyon K. Choi², ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴School Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Although the cardinal feature of gout is inflammatory arthritis, it is also a metabolic condition closely associated with an elevated uric acid burden and…
Abstract Number: 2844 • 2017 ACR/ARHP Annual Meeting
Risk of Cardiovascular Events in Older Patients with Gout Initiating Febuxostat Versus Allopurinol: A Population-Based Cohort Study
MaryAnn Zhang¹, Jun Liu², Eun Ha Kang³, Rishi J. Desai⁴, Tuhina Neogi⁵, Daniel H. Solomon¹ and Seoyoung C. Kim¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ⁵Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Gout, a disorder of uric acid deposition, is commonly treated with xanthine oxidase inhibitors like febuxostat and allopurinol. While it is well-known that patients…
Abstract Number: 871 • 2017 ACR/ARHP Annual Meeting
Coronary Microvascular Dysfunction in Rheumatoid Arthritis Compared to Diabetes Mellitus in Patients without Obstructive Coronary Artery Disease
Katherine P. Liao¹, Gabrielle Cremone², Ethan Lam², Zhi Yu¹, Jon M. Hainer³, Victoria Morgan³, Courtney Bibbo³ and Marcelo Di Carli³, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³Nuclear Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Patients with DM have increased coronary microvascular dysfunction (CMD) compared to the general population, leading to higher rates of cardiac death despite normal perfusion…
Abstract Number: 1558 • 2017 ACR/ARHP Annual Meeting
Changes in Blood Pressure with TNF Inhibitors for Psoriatic Arthritis
Birju D. Bhatt¹, J. Lynn Palmer², Jeffrey R. Curtis³, Sathya Velkuru⁴ and Joel Kremer⁵, ¹Medicine, div-of Rheumatology, Albany Medical College, Albany, NY, ²Corrona Research Foundation, Albany, NY, ³Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, Albany Medical College, Albany, NY, ⁵Albany Medical College and the Center for Rheumatology, Albany, NY
Background/Purpose: Psoriasis is a complex disorder with cutaneous and rheumatological manifestations affecting 2-3% of the population of the Western world. The prevalence of hypertension (HTN)…
Abstract Number: 2178 • 2017 ACR/ARHP Annual Meeting
Metabolic Osteoarthritis: Relation of Cardiovascular Disease and Diabetes to Knee Osteoarthritis
Laura Kuusalo¹, David T. Felson², Carrie Brown³, Cora E. Lewis⁴, James Torner⁵ and Tuhina Neogi², ¹University of Turku and Turku University Hospital, Turku, Finland, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Boston University School of Public Health, Boston, MA, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵University of Iowa, Iowa City, IA
Background/Purpose: Metabolic changes or low-grade inflammation related to cardiovascular disease (CVD) and diabetes have been hypothesized to contribute to the development of OA. Prior studies…
Abstract Number: 2846 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in Gout: Novel Findings of Elevated Risk of Renal-Related and Decreased Risk of Dementia-Related Death
Ana Beatriz Vargas-Santos¹, Tuhina Neogi², Geraldo Castelar-Pinheiro¹ and Aleksandra Turkiewicz³, ¹Internal Medicine - Rheumatology, State University of Rio de Janeiro, Rio de Janeiro, Brazil, ²Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, ³Clinical Sciences Lund, Orthopedics, Clinical Epidemiology Unit, Lund University, Lund, Sweden
Background/Purpose: There is recognized higher mortality among gout patients, with cardiovascular (CV) mortality having been previously reported. The present study aimed to examine cause-specific mortality…
Abstract Number: 964 • 2017 ACR/ARHP Annual Meeting
Atherogenic Potency of Plasma from Persons with Autoimmune Rheumatic Disorders: Comparative Effects on Cholesterol Flux in Human Macrophages
Andrew Maidhof¹, Allison B. Reiss^1,2, Lora J. Kasselman², Elise Belilos¹, Kristina Belostocki¹, Gary Rosenblum¹, Lois Bonnetti¹, Melissa Fazzari², Joshua DeLeon¹ and Steven E. Carsons^1,2, ¹NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, ²NYU Winthrop University Hospital, Winthrop Research Institute, Mineola, NY
Background/Purpose: Although the risk of atherosclerotic cardiovascular disease and abnormalities in cholesterol transport have been demonstrated in rheumatoid arthritis (RA), lupus (SLE) and, to a…
Abstract Number: 1583 • 2017 ACR/ARHP Annual Meeting
Increase in Arginase Activity and Related Arginine Metabolites in Patients with Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA): Potential Mechanisms for Endothelial Dysfunction
M. Elaine Husni¹, Vandana Rai², Marcia Leon Rabanal³ and Unnikrishnan Chandrasekharan⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cellular and Molecular Medicine, Cleveland Clinic Foundation, Cleveland, OH, ³Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁴Department of Cellular and Molecular Medicine, Cleveland Clinic, Cleveland, OH
Background/Purpose: A high prevalence of CVD exists among patients with PsA and RA. The cardiovascular morbidity and mortality are hypothesized to be due in part…
Abstract Number: 2246 • 2017 ACR/ARHP Annual Meeting
Impact of Patient Education Tool to Increase Cardiovascular Risk Konwledge, Attitudes, and Behaviors in Patietns with Rheumatoid Arthritis
Lisa Zickuhr¹, William Messner², Abby Abelson³ and M. Elaine Husni⁴, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ³Department of Rheumatologic & Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH, ⁴Cleveland Clinic, Cleveland, OH
Background/Purpose: Rheumatoid arthritis (RA) raises cardiovascular disease (CVD) risk, yet RA patients underestimate their personal risk. The principle of self-management posits patients will be…
Abstract Number: 2883 • 2017 ACR/ARHP Annual Meeting
Prevalence of Cardiovascular Risk Factors and Subclinical Cardovacular Disease in Psoriatic Arthritis
María Paz Martínez-Vidal¹, Cristina Fernández-Carballido², Mariano Andres³, Vega Jovaní⁴, Carlos Santos⁵, Maria Nieves Martínez Alberola⁶, Francisca Sivera⁷ and Raquel Martin-domenech⁶, ¹Rheumatology, Hospital general universitario de Alicante, Alicante, Spain, ²Hospital General Universitario de Elda, Elda, Spain, ³RHEUMATOLOGY, Hospital general universitario de Alicante, Alicante, Spain, ⁴Reumatología, Hospital general universitario de Alicante, Alicante, Spain, ⁵Rheumatology, Hospital de Alcoy, Alcoy, Spain, ⁶Rheumatology, Hospital General Universitario de Elda, Elda, Spain, ⁷Sección de Reumatología, Hospital General Universitario de Elda., Elda, Spain
Background/Purpose: SCORE tables underestimate the Cardiovascular Risk (CVR) for patients with Rheumatoid Arthritis (RA) and EULAR recommends multiplying by 1.5 the CVR obtained from them…
Abstract Number: 989 • 2017 ACR/ARHP Annual Meeting
Impact of DMARD Treatment on Risk of Repeat Cardiovascular Events Among Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Psoriasis
Jeffrey A. Sparks¹, Tamara Lesperance², Neil A. Accortt³ and Daniel H. Solomon⁴, ¹Rheumatology, Immunology, and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²DOCS Global, Inc., North Wales, PA, ³Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ⁴Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Chronic inflammatory diseases such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis (PsO) increase the risk of cardiovascular (CV) disease. However, it is…
Abstract Number: 1586 • 2017 ACR/ARHP Annual Meeting
Resistant Hypertension Is Associated with Inflammation, Renal Function, and Increased Mortality in Patients with Systemic Lupus Erythematosus
Jocelyn Gandelman¹, Megan Shuey², April Barnado³, Li Wang⁴, C. Michael Stein³ and Cecilia P. Chung³, ¹Vanderbilt University School of Medicine, Nashville, TN, ²Department of Pharmacology, Vanderbilt University, Nashville, TN, ³Medicine, Vanderbilt University Medical Center, Nashville, TN, ⁴Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Resistant hypertension (RHTN) is defined as blood pressure that remains >140/90 mm Hg despite concurrent use of three different antihypertensive drugs. RHTN has an…
Abstract Number: 2351 • 2017 ACR/ARHP Annual Meeting
Are Sedentary Behavior and Reduced Physical Activity Associated with Long-Term Cardiovascular Risk in Individuals with Rheumatoid Arthritis?
Nevin Hammam^1,2, Victor Ezeugwu¹, Dax Rumsey³, Trish Manns⁴ and Lesley Pritchard-Wiart^5,6, ¹University of Alberta, Edmonton, AB, Canada, ²Rheumatology and Rehabilitation Department, University of Assiut, Assiut, Egypt, ³Stollery Children's Hospital, Edmonton, AB, Canada, ⁴University of Alberta, edmonton, AB, Canada, ⁵Glenrose Rehabilitation Hospital Edmonton, Edmonton, AB, Canada, ⁶Physical Therapy, University of Alberta, Edmonton, AB, Canada
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk for cardiovascular disease (CVD) with subsequent morbidity and mortality1. It is well known that prolonged…
Abstract Number: 2913 • 2017 ACR/ARHP Annual Meeting
the Periodontal Pathogen Aggregatibacter Actinomycetemcomitans Is Associated with Subclinical Coronary Atherosclerosis in Rheumatoid Arthritis
Jon T. Giles¹, Jesper Reinholdt², Joan Bathon³, Felipe Andrade⁴ and Maximilian F. Konig⁵, ¹Division of Rheumatology, Columbia University, College of Physicians and Surgeons, New York, NY, ²Department of Biomedicine, Aarhus University, Aarhus, Denmark, ³Division of Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁴Medicine/Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The oral pathogen Aggregatibacter actinomycetemcomitans (Aa) generates citrullinated proteins targeted by autoantibodies in RA through its pore-forming toxin leukotoxin A (LtxA). Aa-derived LtxA is…
Abstract Number: 1087 • 2017 ACR/ARHP Annual Meeting
Rheumatology Clinic Smoking Cessation Protocol Markedly Increases Quit Line Referrals
Christie M. Bartels¹, Edmond Ramly², Daniel Panyard³, Diane Lauver⁴, Heather Johnson⁵, Zhanhai Li⁶, Emmanuel Sampene⁷, Megan Piper⁸ and Patrick McBride⁵, ¹Rheumatology/Medicine, University of Wisconsin - Madison, Madison, WI, ²Industrial and Systems Engineering, University of Wisconsin College of Engineering, Madison, WI, ³Population Health, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁴University of Wisconsin-Madison School of Nursing, Madison, WI, ⁵Cardiology/Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁶Biostatistics and Medical Informatics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁷Biostatistics, University of Wisconsin School of Medicine and Public Health, Madison, WI, ⁸University of Wisconsin Center for Tobacco Research and Intervention, Madison, WI
Background/Purpose: Smoking predicts higher incidence, greater severity, and reduced treatment responses in rheumatoid arthritis, lupus, and spondyloarthritis. However, cessation advice and quit line referral occur…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].